China Business Law Journal: 3D Medicines Taps Han Kun for IP Advice in Hong Kong IPO
December 22, 2022
O’Melveny represented 3D Medicines Inc., an oncology medical research and development company, in its initial public offering and listing of shares on the Main Board of the Hong Kong Stock Exchange. The IPO offering size was approximately HK$408 million (approximately US$52 million). The O’Melveny team, which was led by partners Ke Geng and Ke Zhu, advised 3D Medicines on both US and Hong Kong law and drafted the prospectus. O’Melveny partners Rob Plesnarski and Kurt Berney advised on tax issues.
Read the full article here.